SCHEMBL16362385

SCHEMBL16362385

Cc1cc2oc(=O)n(C)c2cc1-c1ccc(NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.48
▸ CA1 P00915 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ PSMB8 P28062 1/20 0.46
▸ PRKDC P78527 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.42
▸ CYP17A1 P05093 2/20 0.40
▸ CD274 Q9NZQ7 1/20 0.40
▸ BRD4 O60885 1/20 0.39
▸ CREBBP Q92793 1/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ USP2 O75604 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ IL2 P60568 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17766385 0.85 KDM4E (0.48) KDM4EMAPK1USP2HSD17B10IL2
SCHEMBL16362389 0.82 CA12 (0.52) CA12CA1CA9PSMB8PRKDC
SCHEMBL17766373 0.76 MAPT (0.55) KDM4EHSD17B10IL2TDP1TP53
SCHEMBL16362398 0.74 IL2 (0.63) KDM4EIL2TP53HTTPKM
SCHEMBL1701233 0.74 CA12 (0.55) CA12CA1CA9PSMB8PRKDC
SCHEMBL16362040 0.73 IL2 (0.59) IL2
SCHEMBL4925091 0.71 CA9 (0.82) CA12CA1CA9PSMB8KDM4E
SCHEMBL23577752 0.70 LMNA (0.43) CA12CA1CA9KDM4EPOLB
SCHEMBL20865536 0.70 CYP17A1 (0.68) CA12CA1CA9PSMB8PRKDC
SCHEMBL16362052 0.69 PKM (0.41) KDM4EBRD4MAPK1IL2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US disclosed
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US disclosed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US disclosed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US disclosed
WO-2014203217-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2014-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS RYR2, NR2C2, CACNA1E CA12 736/4885CA1 497/4885CA9 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback